Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High-dose Hydroxychloroquine for Mild COVID-19
NCT04351620Phase 1Completed
- Sponsor
- University of Chicago
- Start
- Apr 2020
- Primary completion
- Jun 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of hydroxychloroquine in coronavirus disease 2019 (COVID-19), sponsored by University of Chicago. Primary endpoints: Tolerability of high dose HCQ as measured by HCQ dose modification and ability to complete course at 14 days, Tolerability of high dose HCQ as measured by discontinuation of HCQ before end of course at 14 days and 1 more. Started Apr 2020; status: completed.
02
Drugs
hydroxychloroquine
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04351620.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04351620.